Identity
What is KPV?
A three-residue peptide, Lys-Pro-Val, taken up into cells by the PepT1 transporter.

Research reference · Skin & Collagen
KPV is the tripeptide lysine-proline-valine, the C-terminal end of alpha-MSH. It is studied in cell and mouse models of inflammation, especially colitis.
Published by Elevated Pharma ·
Identity
A three-residue peptide, Lys-Pro-Val, taken up into cells by the PepT1 transporter.
Research context
Published work is preclinical: colitis models in mice, skin and macrophage cell studies, and new oral delivery systems. No completed human trial was found.
Evidence boundary
Cell and animal findings are not human outcome evidence.
U.S. status · November 7, 2026
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
HHS published an enforcement-discretion policy covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 for licensed pharmacies and physicians. Comments close November 13, 2026.
Read the sourceFDA’s Pharmacy Compounding Advisory Committee voted on seven peptides over July 23–24, recommending six and declining emideltide (DSIP).
Read the sourceKey studies
Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.
Search all 49 PubMed records for KPV · Counts and selections checked November 7, 2026.
Reference identifiers
Database identity describes the reference substance, not any specific material or lot.
Official & primary sources
Citation does not imply an Elevated Pharma partnership or endorsement.